Whoop raises $575M

Whoop just raised $575 million at a $10.1 billion valuation on March 31, 2026, which is a huge jump from the $3.6 billion valuation it disclosed after its 2021 round. The company said the new money will fund global expansion and a push beyond fitness tracking into a broader health platform. (whoop.com) This is not a watch company in the usual sense. Whoop sells a screenless wrist strap tied to a membership, so the product is less “buy hardware once” and more “pay every month for a stream of sleep, strain, and recovery data.” (nytimes.com) Investors backed that model because it is already big. Whoop said it now has more than 2.5 million members worldwide, and it said 2025 bookings grew 103 percent year over year to a $1.1 billion run rate while operating cash flow stayed positive. (businesswire.com) The names in the round show where Whoop wants to go next. Collaborative Fund led the deal, and the investor list included Abbott, Mayo Clinic, Qatar Investment Authority, Mubadala, Cristiano Ronaldo, LeBron James, and Rory McIlroy. (whoop.com) Abbott and Mayo Clinic are the important clues there. Abbott makes medical devices and diagnostics, and Mayo Clinic is one of the best-known hospital systems in the United States, so this round ties Whoop more tightly to healthcare than a normal consumer gadget startup. (whoop.com) Whoop’s pitch is that years of continuous body data are more useful than a single snapshot at a doctor’s office. Collaborative Fund said Whoop has collected more than 24 billion hours of physiological data from over 2.5 million members, which is the kind of long-running dataset companies hope can power coaching, risk alerts, and new health products. (collabfund.com) That ambition also explains why the company talks less about steps and more about “personalized health.” Bloomberg reported that founder Will Ahmed has described Whoop as a future “health operating system” that could use artificial intelligence to analyze data continuously and eventually predict conditions like heart attacks and strokes. (bloomberg.com) But moving from wellness to health care is where the easy story ends. On July 14, 2025, the United States Food and Drug Administration sent Whoop a warning letter saying its Blood Pressure Insights feature was being marketed in the United States without clearance or approval as a medical device. (fda.gov) Whoop answered that its blood pressure feature was a wellness tool tied to sleep, stress, recovery, and exercise, not a diagnosis or treatment product. That fight matters because every wearable company wants to sound medically useful, but the closer the claim gets to diagnosis, the more likely regulators step in. (whoop.com) So this funding round is really a bet on a narrow path. Whoop has to turn a consumer subscription business into something trusted by employers, health systems, and regulators without losing the speed that got it to 2.5 million members in the first place. (medtechdive.com) The size of the round says investors think that path is still open. TechCrunch reported that the new valuation is nearly triple Whoop’s last reported valuation, which means the market is rewarding companies that can turn wearable data into repeat revenue before they have fully crossed into regulated medicine. (techcrunch.com)